الفهرس 
Efficacy of the management of node negative early stage breast cancer using 1% methylene blue in sentinel lymph node biopsy
AbstractOnly 14 pages are availabe for public view
 |  | from | 204 |  |  |
| | | from | 204 | | |
Abstract
Background: Breast cancer is the most common type of cancer and the second leading cause of cancerdeaths among women. Early-stage diagnosis of breast cancer increases the chances of survival and, therefore, reduces mortality rates. Accurate staging and proper management of axillary lymph nodes are important for the treatment of breast cancer. Sentinel lymph node biopsy (SLNB) provides accurate assessment of nodal status.Objective: Evaluation the safety, the accuracy and the cost of the application of sentinel lymph node biopsy (SLNB)using methylene blue 1% (MB 1%) in cases of node negative early stage breast cancer. Methods: This study is a prospective case series study, was conducted at Kasr Al-Ainyuniversity Hospitals, Faculty of Medicine, Cairo University between December 1st 2017 and October 1st 2019.Fifty-two female patients with node negative early stage breast cancer who agreed on undergoing BCS, Sentinel Lymph node biopsy using 1% methylene blue and frozen section examination then managed according to ACOSOG Z0011 criteria with follow-up of average 12 monthsrage 12 months follow up showed no locoregional recurrence